Brokerages Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) PT at $336.30

Key Points

• BeOne Medicines Ltd. has received a consensus rating of "Buy" from nine analysts, with eight recommending a buy and one a strong buy, and an average one-year price target of $336.30.
• Insider transactions indicate significant sales, including an insider selling 5,000 shares at an average price of $350.06, contributing to a total sale of $56.8 million worth of stock in the last quarter.
• The company's stock recently opened at $334.40, marking a 2.5% decline, while it has a market capitalization of $36.65 billion and reported earnings per share of $0.84 for the last quarter.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has received an average recommendation of "Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $336.30.

ONC has been the subject of a number of analyst reports. Guggenheim raised their price objective on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a research report on Thursday, July 17th. Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Finally, Zacks Research upgraded shares of BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research report on Thursday.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC traded up $3.42 during midday trading on Friday, reaching $337.82. 112,332 shares of the company's stock were exchanged, compared to its average volume of 422,571. The company's 50 day simple moving average is $308.71 and its two-hundred day simple moving average is $268.33. The firm has a market capitalization of $37.03 billion, a PE ratio of -195.27 and a beta of 0.21. BeOne Medicines has a 12 month low of $170.99 and a 12 month high of $351.27. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.36. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. Equities research analysts expect that BeOne Medicines will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $337.00, for a total value of $898,105.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 10,006 shares of the firm's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $325.53, for a total transaction of $3,257,253.18. The disclosure for this sale can be found here. Insiders have sold a total of 183,322 shares of company stock worth $55,372,357 over the last ninety days. Company insiders own 6.62% of the company's stock.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. Anchor Investment Management LLC acquired a new stake in BeOne Medicines in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in BeOne Medicines in the 2nd quarter valued at about $28,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the 2nd quarter valued at about $35,000. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines in the 2nd quarter valued at about $39,000. Finally, Signaturefd LLC acquired a new stake in BeOne Medicines in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.